ATE546448T1 - Urotensin-ii-rezeptorantagonisten - Google Patents

Urotensin-ii-rezeptorantagonisten

Info

Publication number
ATE546448T1
ATE546448T1 AT09791047T AT09791047T ATE546448T1 AT E546448 T1 ATE546448 T1 AT E546448T1 AT 09791047 T AT09791047 T AT 09791047T AT 09791047 T AT09791047 T AT 09791047T AT E546448 T1 ATE546448 T1 AT E546448T1
Authority
AT
Austria
Prior art keywords
urotensin
receptor antagonists
compounds
formula
prodrugs
Prior art date
Application number
AT09791047T
Other languages
English (en)
Inventor
William Kinney
Diane Luci
Bruce Maryonoff
Edward Lawson
Shyamali Ghosh
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE546448T1 publication Critical patent/ATE546448T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT09791047T 2008-08-02 2009-07-31 Urotensin-ii-rezeptorantagonisten ATE546448T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13763408P 2008-08-02 2008-08-02
PCT/US2009/052403 WO2010017105A1 (en) 2008-08-02 2009-07-31 Urotensin ii receptor antagonists

Publications (1)

Publication Number Publication Date
ATE546448T1 true ATE546448T1 (de) 2012-03-15

Family

ID=41259404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09791047T ATE546448T1 (de) 2008-08-02 2009-07-31 Urotensin-ii-rezeptorantagonisten

Country Status (7)

Country Link
US (1) US9079896B2 (de)
EP (1) EP2326644B1 (de)
JP (1) JP2011529966A (de)
AT (1) ATE546448T1 (de)
CA (1) CA2732762A1 (de)
ES (1) ES2379762T3 (de)
WO (1) WO2010017105A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049120A4 (de) 2006-07-31 2011-09-07 Janssen Pharmaceutica Nv Urotensin-ii-rezeptorantagonisten
PH12013501800A1 (en) * 2011-03-15 2013-10-14 L Livermore Nat Security Llc Tricyclic gyrase inhibitors
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629266A (en) * 1969-03-03 1971-12-21 Miles Lab (phenyl piperidino alkyl)3 4-dihydrocarbostyrils
US6546112B1 (en) * 1993-11-18 2003-04-08 Digimarc Corporation Security document with steganographically-encoded authentication data
WO1998052919A1 (en) 1997-05-21 1998-11-26 Japan Tobacco Inc. Phthalimide derivatives and pharmaceutical containing said derivatives
CA2291630A1 (en) * 1997-05-30 1998-12-03 Tetsutaro Niizato Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same
JP2001511448A (ja) * 1997-07-31 2001-08-14 セルジーン コーポレイション 置換アルカノヒドロキサム酸およびTNFαレベルの減少方法
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
DE19933611A1 (de) * 1999-07-17 2001-01-18 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von Aminen durch homogen katalysierte reduktive Aminierung von Carbonylverbindungen
EP1244452B1 (de) * 1999-12-21 2003-09-17 SmithKline Beecham Corporation Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten
GB0027705D0 (en) * 2000-11-11 2000-12-27 S P A Novel compounds
EP1351688A4 (de) 2000-12-11 2006-01-04 Smithkline Beecham Corp Urotensin-ii rezeptorantagonisten
DE10138140A1 (de) * 2001-08-09 2003-02-20 Degussa Verfahren zur Herstellung von Aminen durch reduktive Aminierung von Carbonylverbindungen unter Transfer-Hydrierungsbedingungen
NZ533566A (en) 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US6660736B2 (en) * 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
GB0209244D0 (en) 2002-04-23 2002-06-05 Glaxo Group Ltd Compounds
US20040077529A1 (en) 2002-06-10 2004-04-22 Per-Fredrik Lehmann Urotensin II receptor agents
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
CN1784382A (zh) 2003-03-12 2006-06-07 细胞基因公司 7-氨基-异吲哚基化合物及其药物用途
ES2362484T3 (es) 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
WO2005034873A2 (en) 2003-10-09 2005-04-21 Smithkline Beecham Corporation A method for reducing anti-neoplastic agent induced side-effects
WO2005056540A1 (en) * 2003-12-08 2005-06-23 Warner-Lambert Company Llc Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia
WO2005072226A2 (en) 2004-01-19 2005-08-11 Smithkline Beecham Corporation Use of urotensin-ii receptor antagonists in the treatment of inflammatory bowel diseases
WO2005102317A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
MX2008001292A (es) * 2005-07-29 2008-03-25 Hoffmann La Roche Nuevos derivados de indol-3-il-carbonil-piperidina y piperazina.
TW200804347A (en) * 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
EP2049120A4 (de) 2006-07-31 2011-09-07 Janssen Pharmaceutica Nv Urotensin-ii-rezeptorantagonisten
PA8782701A1 (es) * 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv Antagonistas del receptor de urotensina ii

Also Published As

Publication number Publication date
JP2011529966A (ja) 2011-12-15
US20100029616A1 (en) 2010-02-04
ES2379762T3 (es) 2012-05-03
CA2732762A1 (en) 2010-02-11
EP2326644A1 (de) 2011-06-01
US9079896B2 (en) 2015-07-14
WO2010017105A1 (en) 2010-02-11
EP2326644B1 (de) 2012-02-22

Similar Documents

Publication Publication Date Title
JOP20180103A1 (ar) مركب صيدلاني
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
GEAP202213376A (en) Inhibitors of influenza viruses replication
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA201270216A1 (ru) Фармацевтический состав
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201071329A1 (ru) Диамидные производные адамантана и их применение
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
IN2014CN04530A (de)
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы